Receipt date: 01/25/2007

10591271 - GAU: 16

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail In an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Oated: <u>January 22, 2007</u>

Signature: (Dawn Clas

Docket No.: WIBL-P01-035

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Harbison et al.

Application No.: 10/591,271

Confirmation No.: N/A

Filed: August 31, 2006

Art Unit: N/A

For:

BIOLOGICALLY-ACTIVE DNA-BINDING

Examiner: Not Yet Assigned

SITES AND RELATED METHODS

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR 1.97, Applicants hereby make of record the following additional documents. A PTO Form SB/08 and a full copy of each of the documents required under 37 CFR 1.98(a)(2) accompany this statement.

Applicants have become aware of the following documents, cited in an International Search Report issued September 19, 2005, during the prosecution of International Application No. PCT/US2005/007249, which corresponds to the above referenced application, and in accordance with 37 CFR 1.97(c) and (e)(1) or (b)(3), hereby submits these documents for the Examiner's consideration. These documents are cited on the enclosed PTO Form SB/08, and a copy of the International Search Report and of each document required under 37 CFR 1.98(a)(2) cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited documents are material, that an exhaustive search has been conducted, or that no other relevant information exists.

10330791_1

Receipt date: 01/25/2007 10591271 - GAU: 1634

į

Application No.: 10/591,271 Docket No.: WIBL-P01-035

Nor shall the citation of any document herein be construed *per se* as a representation that such document is prior art. Moreover, Applicants understand the Examiner will make an independent evaluation of the cited documents.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. WIBL-P01-035.

Dated: January 22, 2007

Respectfully submitted,

Ignacio Perez de la Cruz

Registration No.: 55,535

FISH & NEAVE IP GROUP, ROPES & GRAY

LLP

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys/Agents For Applicant

Receipt date: 01/25/2007

O P E 123

PTO/SB/08a/b (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. OEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

to respond to a collection of information unless it contains a valid OMB control number.				
Complete if Known				
Application Number	10/591,271			
Filing Date	August 31, 2006			
First Named Inventor	Christopher Harbison			
Art Unit	N/A			
Examiner Name	Not Yet Assigned			
Attorney Docket Number	WIBL-P01-035			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-OD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,109,776	08-29-2000	Haas	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-01/016378	03-08-2001	Whitehead Biomedical Inst	-	1
	BB	WO-02/14550	02-21-2002	Transgenetics Inc et al.		V
	BC	WO-04/053106	06-24-2004	Regulome Corporation		1
	BD	WO-04/087965	10-14-2004	Corgentech, Inc.		Ì
	BE	WO-04/097577	11-11-2004	New York University		ÌÌ
	BF	WO-05/054461				1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance end not considered. Include copy of this form with next communication to epplicant. *CITE NO.: Those epplication(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed efter June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Oocuments at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA	Bar et al., "Computational discovery of gene modules and regulatory networks," Nature Biotechnology, 21(11):1337-1342, (2003).	
	СВ	Hartemink et al., "Combining location and expression data for principled discovery of genetic regulatory network models," Proceedings of the Pacific Symposium on Biocomputing, pages 437-449, (2002).	
	C	Lee et al., "Transcriptional Regulatory Networks in Saccharomyces cerevisiae," Science, 298:799-804, (2002).	
	CD	Mukherjee et al., "Rapid analysis of the DNA binding specificities of transcription factors with DNA microarrays," Nature Genetics, 36(12):1331-1339, (2004).	
	Е	Odom et al., "Control of Pancreas and Liver Gene Expression by HNF Transcription Factors," Science, 303(5662):1378-1381, (2004).	-
	CF	Weinmann et al., "Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis," Genes & Development, 16:235-244, (2002).	
	CG	Wyrick et al., "Deciphering gene expression regulatory networks," Current Opinion in Genetics and Development, 12:130-136, (2002).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place e check merk here if English language Translation is attached.

Examiner	1977 1 7 8 11 1	Date	
Cinnatural	/Ethan Whisenant/	Date	09/18/2008
Signature	Lanan Villoonan	Considered	03/10/2000
			I ==_